Parabilis Medicines To Present Updated Clinical Data For Zolucatetide In Patients With Desmoid Tumors At ESMO Congress 2026

Parabilis Medicines (NASDAQ: PBLS) will present updated clinical data for zolucatetide in patients with desmoid tumors at the ESMO Congress 2026, scheduled for October 23-27, 2026, in Madrid, Spain. The presentation will include data from the ongoing Phase 1/2 trial, focusing on dose optimization to inform the upcoming Phase 3 registrational trial. Zolucatetide has received Fast Track and Orphan Drug Designations from the FDA for treating desmoid tumors.